- Home
- RRGB vs GANX Comparison
RRGB vs GANX Comparison
Compare RRGB & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRGB | GANX |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 78.2M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RRGB | GANX |
|---|---|---|
| Price | $3.63 | $1.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $9.00 | $7.50 |
| AVG Volume (30 Days) | 236.8K | ★ 534.8K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,315,014,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $1.41 |
| 52 Week High | $7.52 | $4.34 |
Technical Indicators
Market Signals| Indicator | RRGB | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 46.29 |
| Support Level | $3.20 | $1.66 |
| Resistance Level | $4.41 | $2.11 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 19.49 | 38.82 |
Price Performance
Historical ComparisonAbout RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.